Although CEA is most commonly associated with colorectal cancer, it can also be elevated in other malignancies, such as breast, liver, stomach, and pancreas cancer, suggesting that CEA is most widely used as a tumour-associated serum biomarker16,17. Here, CEACAM5 is linked to colorectal cancer.